NO326546B1 - Pyridinderivater, fremgangsmate for fremstilling derav samt farmasoytisk preparat omfattende en slik forbindelse - Google Patents

Pyridinderivater, fremgangsmate for fremstilling derav samt farmasoytisk preparat omfattende en slik forbindelse Download PDF

Info

Publication number: NO326546B1
Authority: NO; Norway
Prior art keywords: compound; hydrogen; formula; phenyl; chlorophenyl
Prior art date: 2001-03-26

Application number

NO20034122A

Other languages

English (en)

Norwegian (no)

Other versions

NO20034122L (no

NO20034122D0 (no

Inventor

Peter Gull

Andrew James Culshaw

Allan Hallett

Hong-Yong Kim

Kaspar Zimmermann

Yugang Liu

Max Peter Seiler

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-26

Filing date

2003-09-16

Publication date

2009-01-05

2001-03-26 Priority claimed from GB0107505A external-priority patent/GB0107505D0/en

2003-09-16 Application filed by Novartis Ag filed Critical Novartis Ag

2003-09-16 Publication of NO20034122L publication Critical patent/NO20034122L/no

2003-09-16 Publication of NO20034122D0 publication Critical patent/NO20034122D0/no

2009-01-05 Publication of NO326546B1 publication Critical patent/NO326546B1/no

Links

150000001875 compounds Chemical class 0.000 title claims description 37
238000000034 method Methods 0.000 title claims description 10
238000002360 preparation method Methods 0.000 title claims description 7
230000008569 process Effects 0.000 title claims description 4
239000008194 pharmaceutical composition Substances 0.000 title description 3
150000003222 pyridines Chemical class 0.000 title description 2
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 75
229910052739 hydrogen Inorganic materials 0.000 claims description 21
239000001257 hydrogen Substances 0.000 claims description 21
150000003839 salts Chemical group 0.000 claims description 18
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 17
150000002431 hydrogen Chemical class 0.000 claims description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 10
MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 10
238000006243 chemical reaction Methods 0.000 claims description 8
YYASVUNKUYCHIU-UHFFFAOYSA-N 2-(4-chlorophenyl)-1-(dimethylamino)-4,4-dimethylpent-1-en-3-one Chemical compound CN(C)C=C(C(=O)C(C)(C)C)C1=CC=C(Cl)C=C1 YYASVUNKUYCHIU-UHFFFAOYSA-N 0.000 claims description 7
OGJSXKLSNLMPCL-UHFFFAOYSA-N 1-(4-chlorophenyl)-3,3-dimethylbutan-2-one Chemical compound CC(C)(C)C(=O)CC1=CC=C(Cl)C=C1 OGJSXKLSNLMPCL-UHFFFAOYSA-N 0.000 claims description 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
239000004201 L-cysteine Substances 0.000 claims description 5
235000013878 L-cysteine Nutrition 0.000 claims description 5
ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 claims description 5
NHDODQWIKUYWMW-UHFFFAOYSA-N 1-bromo-4-chlorobenzene Chemical compound ClC1=CC=C(Br)C=C1 NHDODQWIKUYWMW-UHFFFAOYSA-N 0.000 claims description 4
239000007864 aqueous solution Substances 0.000 claims description 4
229910052736 halogen Inorganic materials 0.000 claims description 4
150000002367 halogens Chemical class 0.000 claims description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
PJGSXYOJTGTZAV-UHFFFAOYSA-N pinacolone Chemical compound CC(=O)C(C)(C)C PJGSXYOJTGTZAV-UHFFFAOYSA-N 0.000 claims description 4
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 3
238000006254 arylation reaction Methods 0.000 claims description 3
238000010533 azeotropic distillation Methods 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
238000011084 recovery Methods 0.000 claims description 3
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 3
235000019345 sodium thiosulphate Nutrition 0.000 claims description 3
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
239000004480 active ingredient Substances 0.000 claims description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
239000000825 pharmaceutical preparation Substances 0.000 claims description 2
238000000746 purification Methods 0.000 claims description 2
BOBBYBHJYYJHHQ-UHFFFAOYSA-N 7-tert-butyl-6-(4-chlorophenyl)-2-sulfanylidene-1h-pyrido[2,3-d]pyrimidin-4-one Chemical compound CC(C)(C)C1=NC=2NC(=S)NC(=O)C=2C=C1C1=CC=C(Cl)C=C1 BOBBYBHJYYJHHQ-UHFFFAOYSA-N 0.000 claims 1
229940125904 compound 1 Drugs 0.000 claims 1
230000007306 turnover Effects 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 description 30
239000000203 mixture Substances 0.000 description 29
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
239000000243 solution Substances 0.000 description 22
238000010992 reflux Methods 0.000 description 15
208000006673 asthma Diseases 0.000 description 13
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
229910052757 nitrogen Inorganic materials 0.000 description 11
239000002904 solvent Substances 0.000 description 11
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
239000007787 solid Substances 0.000 description 10
208000002193 Pain Diseases 0.000 description 8
235000019441 ethanol Nutrition 0.000 description 8
239000011541 reaction mixture Substances 0.000 description 8
208000004454 Hyperalgesia Diseases 0.000 description 7
230000002757 inflammatory effect Effects 0.000 description 7
239000010410 layer Substances 0.000 description 7
KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
206010061218 Inflammation Diseases 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
210000002683 foot Anatomy 0.000 description 6
239000012044 organic layer Substances 0.000 description 6
208000023504 respiratory system disease Diseases 0.000 description 6
239000000725 suspension Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
102000011040 TRPV Cation Channels Human genes 0.000 description 5
108010062740 TRPV Cation Channels Proteins 0.000 description 5
229960000583 acetic acid Drugs 0.000 description 5
239000002253 acid Substances 0.000 description 5
239000011575 calcium Substances 0.000 description 5
239000000706 filtrate Substances 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
201000004624 Dermatitis Diseases 0.000 description 4
239000012981 Hank's balanced salt solution Substances 0.000 description 4
101000633069 Homo sapiens Transient receptor potential cation channel subfamily V member 1 Proteins 0.000 description 4
208000035154 Hyperesthesia Diseases 0.000 description 4
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
241000700159 Rattus Species 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
229910052791 calcium Inorganic materials 0.000 description 4
YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000001914 filtration Methods 0.000 description 4
102000045756 human TRPV1 Human genes 0.000 description 4
230000000414 obstructive effect Effects 0.000 description 4
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
BWYGMIYEADAIGW-UHFFFAOYSA-N 6-amino-2-sulfanylidene-1h-pyrimidin-4-one;hydrate Chemical compound O.NC1=CC(=O)NC(=S)N1 BWYGMIYEADAIGW-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
206010065390 Inflammatory pain Diseases 0.000 description 3
239000000556 agonist Substances 0.000 description 3
239000000730 antalgic agent Substances 0.000 description 3
239000012131 assay buffer Substances 0.000 description 3
239000012298 atmosphere Substances 0.000 description 3
239000002585 base Substances 0.000 description 3
239000003054 catalyst Substances 0.000 description 3
201000010099 disease Diseases 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
208000027866 inflammatory disease Diseases 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
150000002576 ketones Chemical class 0.000 description 3
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
HXRAMSFGUAOAJR-UHFFFAOYSA-N n,n,n',n'-tetramethyl-1-[(2-methylpropan-2-yl)oxy]methanediamine Chemical compound CN(C)C(N(C)C)OC(C)(C)C HXRAMSFGUAOAJR-UHFFFAOYSA-N 0.000 description 3
208000004296 neuralgia Diseases 0.000 description 3
208000021722 neuropathic pain Diseases 0.000 description 3
238000001953 recrystallisation Methods 0.000 description 3
238000005406 washing Methods 0.000 description 3
QATHVLKLWVUSRC-UHFFFAOYSA-N 4-methyl-1-phenylpentan-3-one Chemical compound CC(C)C(=O)CCC1=CC=CC=C1 QATHVLKLWVUSRC-UHFFFAOYSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
208000000094 Chronic Pain Diseases 0.000 description 2
206010009900 Colitis ulcerative Diseases 0.000 description 2
208000011231 Crohn disease Diseases 0.000 description 2
108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
208000022559 Inflammatory bowel disease Diseases 0.000 description 2
208000005615 Interstitial Cystitis Diseases 0.000 description 2
102000004310 Ion Channels Human genes 0.000 description 2
108090000862 Ion Channels Proteins 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
208000019695 Migraine disease Diseases 0.000 description 2
PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical group C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 2
206010033645 Pancreatitis Diseases 0.000 description 2
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
108050004388 Transient receptor potential cation channel subfamily V member 1 Proteins 0.000 description 2
102100029613 Transient receptor potential cation channel subfamily V member 1 Human genes 0.000 description 2
201000006704 Ulcerative Colitis Diseases 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
206010046851 Uveitis Diseases 0.000 description 2
-1 acetylsalicylic acid, propionic acid derivatives Chemical class 0.000 description 2
239000013543 active substance Substances 0.000 description 2
150000001338 aliphatic hydrocarbons Chemical class 0.000 description 2
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
230000003501 anti-edematous effect Effects 0.000 description 2
230000003070 anti-hyperalgesia Effects 0.000 description 2
150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
239000006227 byproduct Substances 0.000 description 2
230000003185 calcium uptake Effects 0.000 description 2
229960002504 capsaicin Drugs 0.000 description 2
235000017663 capsaicin Nutrition 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
238000003271 compound fluorescence assay Methods 0.000 description 2
239000013078 crystal Substances 0.000 description 2
201000003146 cystitis Diseases 0.000 description 2
238000004821 distillation Methods 0.000 description 2
230000000857 drug effect Effects 0.000 description 2
150000002081 enamines Chemical class 0.000 description 2
230000005284 excitation Effects 0.000 description 2
239000012065 filter cake Substances 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
208000013403 hyperactivity Diseases 0.000 description 2
XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
IVSZLXZYQVIEFR-UHFFFAOYSA-N m-xylene Chemical group CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 2
IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
201000008482 osteoarthritis Diseases 0.000 description 2
229910052763 palladium Inorganic materials 0.000 description 2
YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical group [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
239000008177 pharmaceutical agent Substances 0.000 description 2
JAMNHZBIQDNHMM-UHFFFAOYSA-N pivalonitrile Chemical compound CC(C)(C)C#N JAMNHZBIQDNHMM-UHFFFAOYSA-N 0.000 description 2
206010035653 pneumoconiosis Diseases 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
238000010998 test method Methods 0.000 description 2
125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
IBHVWQOHJJPTNV-UHFFFAOYSA-N 1-(4-chlorophenyl)-3,3-dimethylbutan-2-imine;hydrochloride Chemical compound Cl.CC(C)(C)C(=N)CC1=CC=C(Cl)C=C1 IBHVWQOHJJPTNV-UHFFFAOYSA-N 0.000 description 1
KQNBRMUBPRGXSL-UHFFFAOYSA-N 1-(bromomethyl)-4-chlorobenzene Chemical compound ClC1=CC=C(CBr)C=C1 KQNBRMUBPRGXSL-UHFFFAOYSA-N 0.000 description 1
SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
MFEILWXBDBCWKF-UHFFFAOYSA-N 3-phenylpropanoyl chloride Chemical compound ClC(=O)CCC1=CC=CC=C1 MFEILWXBDBCWKF-UHFFFAOYSA-N 0.000 description 1
LNDZXOWGUAIUBG-UHFFFAOYSA-N 6-aminouracil Chemical compound NC1=CC(=O)NC(=O)N1 LNDZXOWGUAIUBG-UHFFFAOYSA-N 0.000 description 1
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
208000033116 Asbestos intoxication Diseases 0.000 description 1
206010003557 Asthma exercise induced Diseases 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
206010006002 Bone pain Diseases 0.000 description 1
101800004538 Bradykinin Proteins 0.000 description 1
206010048962 Brain oedema Diseases 0.000 description 1
208000007596 Byssinosis Diseases 0.000 description 1
208000025480 CHILD syndrome Diseases 0.000 description 1
206010058019 Cancer Pain Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
208000004657 Exercise-Induced Asthma Diseases 0.000 description 1
208000001640 Fibromyalgia Diseases 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
208000027109 Headache disease Diseases 0.000 description 1
206010021137 Hypovolaemia Diseases 0.000 description 1
208000028603 Interstitial lung disease specific to childhood Diseases 0.000 description 1
102100035792 Kininogen-1 Human genes 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
208000029549 Muscle injury Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
230000010799 Receptor Interactions Effects 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
201000010001 Silicosis Diseases 0.000 description 1
239000004133 Sodium thiosulphate Substances 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
208000010040 Sprains and Strains Diseases 0.000 description 1
208000004760 Tenosynovitis Diseases 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
206010046543 Urinary incontinence Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
201000009961 allergic asthma Diseases 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
208000028462 aluminosis Diseases 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
229940025141 anafranil Drugs 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
208000010123 anthracosis Diseases 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229940124572 antihypotensive agent Drugs 0.000 description 1
229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 1
206010003441 asbestosis Diseases 0.000 description 1
238000003556 assay Methods 0.000 description 1
229960000794 baclofen Drugs 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
239000012455 biphasic mixture Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
239000004044 bronchoconstricting agent Substances 0.000 description 1
230000003435 bronchoconstrictive effect Effects 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
239000000872 buffer Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
229960000623 carbamazepine Drugs 0.000 description 1
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
229960000590 celecoxib Drugs 0.000 description 1
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229940111134 coxibs Drugs 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
239000002027 dichloromethane extract Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
239000000428 dust Substances 0.000 description 1
229940011681 elavil Drugs 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
239000012259 ether extract Substances 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
208000024711 extrinsic asthma Diseases 0.000 description 1
239000012458 free base Substances 0.000 description 1
YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
229960002870 gabapentin Drugs 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000002682 general surgery Methods 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
KWHDXJHBFYQOTK-UHFFFAOYSA-N heptane;toluene Chemical compound CCCCCCC.CC1=CC=CC=C1 KWHDXJHBFYQOTK-UHFFFAOYSA-N 0.000 description 1
210000000548 hind-foot Anatomy 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
239000005555 hypertensive agent Substances 0.000 description 1
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
201000010659 intrinsic asthma Diseases 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000003447 ipsilateral effect Effects 0.000 description 1
208000002551 irritable bowel syndrome Diseases 0.000 description 1
238000002955 isolation Methods 0.000 description 1
YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000005906 menstruation Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
201000008383 nephritis Diseases 0.000 description 1
229940087480 norpramin Drugs 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 1
229960001816 oxcarbazepine Drugs 0.000 description 1
229940055692 pamelor Drugs 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
239000008389 polyethoxylated castor oil Substances 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
OGQDIIKRQRZXJH-UHFFFAOYSA-N protriptyline hydrochloride Chemical compound [Cl-].C1=CC2=CC=CC=C2C(CCC[NH2+]C)C2=CC=CC=C21 OGQDIIKRQRZXJH-UHFFFAOYSA-N 0.000 description 1
238000011552 rat model Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
229960000371 rofecoxib Drugs 0.000 description 1
RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
210000003497 sciatic nerve Anatomy 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
208000004003 siderosis Diseases 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000000050 smooth muscle relaxant Substances 0.000 description 1
WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
PODWXQQNRWNDGD-UHFFFAOYSA-L sodium thiosulfate pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[O-]S([S-])(=O)=O PODWXQQNRWNDGD-UHFFFAOYSA-L 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000007962 solid dispersion Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
229940118176 surmontil Drugs 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
238000002636 symptomatic treatment Methods 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229940041597 tofranil Drugs 0.000 description 1
229940035276 tofranil-pm Drugs 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
230000008733 trauma Effects 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
YDGHCKHAXOUQOS-BTJKTKAUSA-N trimipramine maleate Chemical compound [O-]C(=O)\C=C/C([O-])=O.C1CC2=CC=CC=C2[NH+](CC(C[NH+](C)C)C)C2=CC=CC=C21 YDGHCKHAXOUQOS-BTJKTKAUSA-N 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
239000000085 vanilloid receptor antagonist Substances 0.000 description 1
208000001319 vasomotor rhinitis Diseases 0.000 description 1
208000037911 visceral disease Diseases 0.000 description 1
229940045977 vivactil Drugs 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1
239000008096 xylene Substances 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Neurology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Immunology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Vascular Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20034122A 2001-03-26 2003-09-16 Pyridinderivater, fremgangsmate for fremstilling derav samt farmasoytisk preparat omfattende en slik forbindelse NO326546B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0107505A GB0107505D0 (en)	2001-03-26	2001-03-26	Organic compounds
US33828101P	2001-12-06	2001-12-06
PCT/EP2002/003332 WO2002076946A2 (en)	2001-03-26	2002-03-25	Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.

Publications (3)

Publication Number	Publication Date
NO20034122L NO20034122L (no)	2003-09-16
NO20034122D0 NO20034122D0 (no)	2003-09-16
NO326546B1 true NO326546B1 (no)	2009-01-05

Family

ID=26245894

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20034122A NO326546B1 (no)	2001-03-26	2003-09-16	Pyridinderivater, fremgangsmate for fremstilling derav samt farmasoytisk preparat omfattende en slik forbindelse

Country Status (17)

Country	Link
US (1)	US7915264B2 (xx)
EP (1)	EP1377576A2 (xx)
JP (1)	JP4205430B2 (xx)
KR (1)	KR20030083755A (xx)
CN (1)	CN1500089A (xx)
BR (1)	BR0208338A (xx)
CA (1)	CA2441599A1 (xx)
CZ (1)	CZ20032561A3 (xx)
HU (1)	HUP0303623A2 (xx)
IL (1)	IL157815A0 (xx)
MX (1)	MXPA03008754A (xx)
NO (1)	NO326546B1 (xx)
PE (1)	PE20021161A1 (xx)
PL (1)	PL363907A1 (xx)
RU (1)	RU2003130221A (xx)
SK (1)	SK11952003A3 (xx)
WO (1)	WO2002076946A2 (xx)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002016319A1 (en)	2000-08-21	2002-02-28	Pacific Corporation	Novel thiourea compounds and the pharmaceutical compositions containing the same
MXPA03001535A (es)	2000-08-21	2004-12-13	Pacific Corp	Derivados de tiourea novedosos y las composiciones farmaceuticas que contienen los mismos.
EP1471910A2 (en)	2002-01-17	2004-11-03	Neurogen Corporation	Substituted quinazolin-4-ylamine analogues as modulators of capsaicin receptors
EP2033951A3 (en)	2002-02-01	2009-12-23	Euro-Celtique S.A.	2-Piperazine-pyridines useful for treating pain
US6864261B2 (en)	2002-05-02	2005-03-08	Euro-Celtique S.A.	Therapeutic agents useful for treating pain
GB0229808D0 (en) *	2002-12-20	2003-01-29	Glaxo Group Ltd	Novel compositions
ATE450533T1 (de)	2003-02-14	2009-12-15	Glaxo Group Ltd	Carboxamidderivate
EP2281823A3 (en)	2003-05-20	2011-09-07	Ajinomoto Co., Inc.	Anti-inflammatory and analgesic piperidine derivatives
GB0319150D0 (en)	2003-08-14	2003-09-17	Glaxo Group Ltd	Novel compounds
US20070135454A1 (en)	2003-11-14	2007-06-14	Tracy Bayliss	Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1)
GB0412769D0 (en) *	2004-06-08	2004-07-07	Novartis Ag	Organic compounds
WO2006019965A2 (en) *	2004-07-16	2006-02-23	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
JP2008508190A (ja)	2004-07-19	2008-03-21	ノボノルディスクアクティーゼルスカブ	肥満または肥満に関連する疾患および障害の治療におけるカプサイシン受容体の活性の阻害
DE102004039373A1 (de)	2004-08-12	2006-02-23	Grünenthal GmbH	Para-Alkyl-substituierte N-(4-Hydroxy-3-methoxy-benzyl)-zimtsäureamide und deren Verwendung zur Herstellung von Arzneimitteln
KR20060087386A (ko)	2005-01-28	2006-08-02	주식회사 대웅제약	신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
WO2006098554A1 (en) *	2005-03-16	2006-09-21	Amorepacific Corporation	Novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and a pharmaceutical composition containing the same
GB0506147D0 (en) *	2005-03-24	2005-05-04	Merck Sharp & Dohme	Therapeutic agents
GB0509573D0 (en) *	2005-05-11	2005-06-15	Merck Sharp & Dohme	Therapeutic compounds
EP1881988A1 (en) *	2005-05-11	2008-01-30	MERCK SHARP & DOHME LTD.	2,3-substituted fused bicyclic pyrimidin-4(3h)-ones modulating the function of the vanilloid-1 receptor (vr1)
EP2388258A1 (de) *	2005-10-19	2011-11-23	Grünenthal GmbH	Neue Vanilloidrezeptor-Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
GB0525068D0 (en)	2005-12-08	2006-01-18	Novartis Ag	Organic compounds
KR100761222B1 (ko) *	2006-03-08	2007-10-04	성균관대학교산학협력단	약물의존중독을 예방 및 치료하기 위한 바닐로이드 수용체길항제
GB0614471D0 (en)	2006-07-20	2006-08-30	Syngenta Ltd	Herbicidal Compounds
KR20090043583A (ko)	2006-08-23	2009-05-06	뉴로젠 코포레이션	2-펜옥시 피리미디논 유사체
EP1958947A1 (en)	2007-02-15	2008-08-20	Ranbaxy Laboratories Limited	Inhibitors of phosphodiesterase type 4
CL2008001112A1 (es) *	2007-04-20	2008-12-19	Novartis Ag	Usos de compuestos derivados de pirido[2,3-d]pirimidin-4-ona para tratar comezon o un trastorno relacionado con comezon; combinacion de los compuestos con otro farmaco; y uso de la combinacion para tratar la comezon o un trastorno relacionado con comezon.
KR20100039410A (ko) *	2007-07-18	2010-04-15	노파르티스 아게	Ｖｒ－１ 길항제 및 ｃｏｘ－２ 억제제의 상승적 조합물
MX2010005769A (es) *	2008-01-11	2010-11-12	Glenmark Pharmaceuticals Sa	Derivados de pirimidina fusionados como moduladores del trpv3.
WO2009121036A2 (en) *	2008-03-27	2009-10-01	Neurogen Corporation	Substituted aryl pyrimidinone derivatives
JP5372138B2 (ja)	2008-04-18	2013-12-18	テウンファーマシューティカルカンパニー，リミテッド	新規ベンゾオキサジンベンズイミダゾール誘導体、これを含む薬学組成物およびこの用途
US8349852B2 (en)	2009-01-13	2013-01-08	Novartis Ag	Quinazolinone derivatives useful as vanilloid antagonists
WO2011092293A2 (en)	2010-02-01	2011-08-04	Novartis Ag	Cyclohexyl amide derivatives as crf receptor antagonists
JP2013518085A (ja)	2010-02-01	2013-05-20	ノバルティスアーゲー	ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
WO2011095450A1 (en)	2010-02-02	2011-08-11	Novartis Ag	Cyclohexyl amide derivatives as crf receptor antagonists
KR101293384B1 (ko)	2010-10-13	2013-08-05	주식회사 대웅제약	신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
UY34094A (es)	2011-05-27	2013-01-03	Novartis Ag	Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
AU2013255458A1 (en)	2012-05-03	2014-10-09	Novartis Ag	L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
EP3204347A4 (en)	2015-12-23	2018-03-28	Commonwealth Scientific and Industrial Research Organisation	Compounds
CN111393380A (zh) *	2018-07-09	2020-07-10	湖南博隽生物医药有限公司	一种用于治疗慢性炎性痛的辣椒素受体拮抗剂
DE102022104759A1 (de)	2022-02-28	2023-08-31	SCi Kontor GmbH	Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen
CN114605408B (zh) *	2022-03-30	2023-06-16	沈阳药科大学	5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2749344A (en)	1953-01-02	1956-06-05	Burroughs Wellcome Co	Pyrimidine compounds
US5958930A (en)	1991-04-08	1999-09-28	Duquesne University Of The Holy Ghost	Pyrrolo pyrimidine and furo pyrimidine derivatives
JPH09510695A (ja)	1994-01-03	1997-10-28	エイシア・ファーマシュウティカルズ，インコーポレイテッド	８−アザ、６−アザ、および６，８−ジアザ−１，４−ジヒドロキノキサリン−２，３−ジオン類およびそのグリシン／ｎｍｄａリセプターに対するアンタゴニストとしての使用
FR2750862B1 (fr)	1996-07-12	1998-10-16	Dupin Jean Pierre	Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques

2002
- 2002-03-25 SK SK1195-2003A patent/SK11952003A3/sk unknown
- 2002-03-25 CN CNA028073495A patent/CN1500089A/zh active Pending
- 2002-03-25 MX MXPA03008754A patent/MXPA03008754A/es not_active Application Discontinuation
- 2002-03-25 HU HU0303623A patent/HUP0303623A2/hu unknown
- 2002-03-25 IL IL15781502A patent/IL157815A0/xx unknown
- 2002-03-25 RU RU2003130221/04A patent/RU2003130221A/ru not_active Application Discontinuation
- 2002-03-25 JP JP2002576207A patent/JP4205430B2/ja not_active Expired - Fee Related
- 2002-03-25 EP EP02730062A patent/EP1377576A2/en not_active Withdrawn
- 2002-03-25 US US10/469,756 patent/US7915264B2/en not_active Expired - Fee Related
- 2002-03-25 PL PL02363907A patent/PL363907A1/xx not_active Application Discontinuation
- 2002-03-25 CA CA002441599A patent/CA2441599A1/en not_active Abandoned
- 2002-03-25 BR BR0208338-8A patent/BR0208338A/pt not_active IP Right Cessation
- 2002-03-25 KR KR10-2003-7012460A patent/KR20030083755A/ko not_active Application Discontinuation
- 2002-03-25 CZ CZ20032561A patent/CZ20032561A3/cs unknown
- 2002-03-25 WO PCT/EP2002/003332 patent/WO2002076946A2/en not_active Application Discontinuation
- 2002-03-26 PE PE2002000241A patent/PE20021161A1/es not_active Application Discontinuation
2003
- 2003-09-16 NO NO20034122A patent/NO326546B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
PL363907A1 (en)	2004-11-29
IL157815A0 (en)	2004-03-28
KR20030083755A (ko)	2003-10-30
US20040138454A1 (en)	2004-07-15
JP4205430B2 (ja)	2009-01-07
SK11952003A3 (sk)	2004-03-02
RU2003130221A (ru)	2005-04-10
US7915264B2 (en)	2011-03-29
MXPA03008754A (es)	2004-02-18
EP1377576A2 (en)	2004-01-07
CZ20032561A3 (cs)	2003-12-17
WO2002076946A3 (en)	2002-12-27
CN1500089A (zh)	2004-05-26
HUP0303623A2 (hu)	2004-03-01
PE20021161A1 (es)	2003-02-21
WO2002076946A2 (en)	2002-10-03
NO20034122L (no)	2003-09-16
JP2004528312A (ja)	2004-09-16
NO20034122D0 (no)	2003-09-16
BR0208338A (pt)	2004-03-09
CA2441599A1 (en)	2002-10-03

Legal Events

Date	Code	Title	Description
2010-11-01	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO326546B1 (no)	2009-01-05	Pyridinderivater, fremgangsmate for fremstilling derav samt farmasoytisk preparat omfattende en slik forbindelse
EP3197867B1 (en)	2018-11-14	Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same
RU2396261C2 (ru)	2010-08-10	Производные хиназолинона, полезные в качестве ванилоидных антагонистов
EP1910370B1 (en)	2015-04-22	A pyridin quinolin substituted pyrrolo [1,2-b] pyrazole monohydrate as tgf-beta inhibitor
CA2902132C (en)	2020-09-22	Quinazolines as kinase inhibitors
JPH09509188A (ja)	1997-09-16	新規なピリミジン誘導体およびその製造方法
ZA200005881B (en)	2001-08-23	Amide derivatives and nociceptin antagonists.
JP2008534597A (ja)	2008-08-28	ＰＫＣ−θのインヒビターとして有用なピリジン誘導体
EP1339706B1 (en)	2006-04-19	N-type calcium channel antagonists for the treatment of pain
EP1572666B1 (en)	2006-08-09	3h-quinazolin-4-one derivatives
AU2017282903B2 (en)	2021-03-25	Crystals of aniline pyrimidine compound serving as EGFR inhibitor
CZ20003974A3 (en)	2001-05-16	Anhydrate and monohydrate of N-(3-ethinylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate
EP0534706A1 (en)	1993-03-31	Quinazolinones and pyridopyrimidinones useful as angiotensin II antagonists
NO328305B1 (no)	2010-01-25	Kinazolinonderivater, fremgangsmate for fremstilling og en farmasoytisk sammensetning omfattende disse
WO2017071607A1 (zh)	2017-05-04	4H-吡唑并[1,5-α]苯并咪唑类化合物晶型及其制备方法和中间体
EP1309569B1 (en)	2010-10-06	N-aryl-{4-[7-(alkoxy)quinazolin-4-yl]piperazinyl}carboxamide derivatives as PDGFRs inhibitors
EP1309567A2 (en)	2003-05-14	Nitrogenous heterocyclic compounds
NO843292L (no)	1985-02-21	Fremgangsmaate for fremstilling av nye kinolon-derivater
US6841680B2 (en)	2005-01-11	N-type calcium channel antagonists for the treatment of pain
AU2002302469A1 (en)	2002-10-08	Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.
US20040259881A1 (en)	2004-12-23	Nitrogenous heterocyclic compounds
ZA200306636B (en)	2004-08-19	Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.